Price$1.30-0.05 (-3.70%)
01:45 PM04:30 PM
News · 26 weeks42+100%
2026-04-192026-10-11
Mix990d
- SEC Filings4(44%)
- Other2(22%)
- Insider2(22%)
- Leadership1(11%)
Latest news
25 items- INSIDERSEC Form 4 filed by MetaVia Inc.4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERSEC Form 3 filed by MetaVia Inc.3 - MetaVia Inc. (0001638287) (Issuer)
- SECSEC Form 8-K filed by MetaVia Inc.8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical OfficerBrings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including PemvidutideCAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, with particular expertis
- SECMetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference ReductionTissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body following subcutaneous administration, with broad tissue distribution and the highest tissue exposure observed in adipose (fat) tissue.
- SECSEC Form 10-Q filed by MetaVia Inc.10-Q - MetaVia Inc. (0001638287) (Filer)
- SECMetaVia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAll Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-172616-Week Topline Data Expected in the Fourth Quarter of 2026CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update. "During the second quarter of 2026, and subsequently, we continued to execute across both of our clinical development programs while further strengthening the di
- SECMetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of ObesityAll Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mgTopline Data Remains on Track for Fourth Quarter 2026CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 p
- SECMetaVia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- SECSEC Form 424B5 filed by MetaVia Inc.424B5 - MetaVia Inc. (0001638287) (Filer)
- PRLife Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD
- PRLife Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings
- PRMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor ForumCAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET. This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast wi
- PRPresenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live streamMIAMI, June 10, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday June 11, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered,
- PRPresenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live streamMIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayJune 10, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to
- PRBioStem Technologies Announces Appointment of Three New Members to its Board of DirectorsPOMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, effective as of June 5, 2026. In connection with their appointment to the Board of Directors, Mr. Sonenreich has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee, Ms. Hannaway has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Commit
- INSIDERDirector Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Groves Jason L was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Koven Andrew I was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Glickman Mark A was granted 17,186 shares, increasing direct ownership by 499% to 20,629 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
MTVA FAQ
6 questionsWhere does MTVA stock trade?
MetaVia Inc. (MTVA) is listed on NASDAQ.What sector and industry is MTVA in?
MetaVia Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MetaVia Inc. go public?
MetaVia Inc. (MTVA) completed its IPO in 2016.What are analysts saying about MTVA?
MetaVia Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-09-04. Recent price targets cluster around $1200.00.What companies are similar to MTVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MTVA side-by-side with any of them on Quantisnow.How can I track MTVA on Quantisnow?
Quantisnow aggregates MetaVia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTVA to receive live email and push alerts on every new disclosure.